Partners Innovation Fund

Mass General Brigham Ventures, formerly known as Partners Innovation Fund, serves as the dedicated venture capital arm of Mass General Brigham, one of the largest academic medical systems in the United States. Based in Boston, this fund plays a crucial role in translating groundbreaking research and clinical innovations from its affiliated hospitals, including Massachusetts General Hospital and Brigham and Women's Hospital, into viable commercial enterprises. Its primary mission is to provide strategic capital and support to early-stage companies that are developing novel solutions in healthcare, leveraging the vast intellectual and clinical resources of its parent organization.

The fund's investment strategy is deeply rooted in the ecosystem of Mass General Brigham, focusing on innovations that emerge from or align closely with the system's research and development pipeline. This includes a broad spectrum of healthcare sectors such as therapeutics, medical devices, diagnostics, and digital health solutions. Mass General Brigham Ventures typically targets companies in their seed to Series B stages, seeking to be an active partner in their growth. Their unique position allows them to offer not just capital but also invaluable access to scientific expertise, clinical validation pathways, and a network of key opinion leaders within the Mass General Brigham system.

Financially, Mass General Brigham Ventures makes initial investments that typically range from $500,000 to $3,000,000, demonstrating a commitment to supporting early-stage ventures with significant potential. While these are initial checks, the fund also participates in follow-on rounds, providing continued support as portfolio companies mature. The fund has been a consistent investor in the life sciences and health technology space, with a notable track record of backing companies that have gone on to achieve significant milestones. For instance, the fund has been involved in over 28 investment rounds, often taking a lead role in 10 of those, underscoring its active participation in shaping its portfolio.